Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
19.87
+0.81 (4.25%)
At close: Oct 8, 2025, 4:00 PM EDT
19.87
0.00 (0.00%)
After-hours: Oct 8, 2025, 4:04 PM EDT
Oculis Holding AG Revenue
Oculis Holding AG had revenue of 261.00K CHF in the quarter ending June 30, 2025, with 6.53% growth. This brings the company's revenue in the last twelve months to 764.00K, down -12.28% year-over-year. In the year 2024, Oculis Holding AG had annual revenue of 686.00K, down -22.31%.
Revenue (ttm)
764.00K CHF
Revenue Growth
-12.28%
P/S Ratio
1,084.12
Revenue / Employee
15,592 CHF
Employees
49
Market Cap
1.04B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
Dec 31, 2020 | 993.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
OCS News
- 1 hour ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 2 days ago - Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy - GlobeNewsWire
- 12 days ago - Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities - GlobeNewsWire
- 16 days ago - Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS - GlobeNewsWire
- 4 weeks ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 4 weeks ago - Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 - GlobeNewsWire
- 5 weeks ago - Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences - GlobeNewsWire
- 5 weeks ago - Oculis to Participate in Upcoming September Investor Conferences - GlobeNewsWire